FDA Bans Import of Drugs from Dr. Reddy's Mexico Site - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA Bans Import of Drugs from Dr. Reddy's Mexico Site


ePT--the Electronic Newsletter of Pharmaceutical Technology

FDA banned the importation of products manufactured at the Mexican unit of Dr. Reddy’s Laboratories, according to Reuters. The import ban is a result of the company’s failure to correct the violations listed in a June 3, 2011, Warning Letter to the agency’s satisfaction.

FDA inspected the Cuernavaca, Mexico, facility, which manufactures active pharmaceutical ingredients (APIs), on Nov. 8–11, 2010, and found several cGMP violations. In the letter, the agency wrote that Dr. Reddy’s had not validated analytical methods for testing APIs, and that the company’s quality unit was not ensuring that APIs manufactured at the site were in compliance with cGMP and met specifications for quality and purity. In addition, FDA found the firm’s cleaning validation to be incomplete for nondedicated manufacturing equipment. Finally, the agency wrote that the site’s out-of-specification investigations did not include an analysis of all available data.

Dr. Reddy’s responded to FDA’s initial observations by implementing several corrective actions. In the Warning Letter, FDA called the company’s response insufficient and asked for additional data and corrective actions.

“Until all corrections have been completed and FDA has confirmed corrections of the deviations and your firm’s compliance with cGMP, FDA may withhold approval of any new applications or supplements listing your firm as an API manufacturer,” said the letter. “In addition, failure to correct these deviations may result in FDA refusing admission of articles manufactured at Industrias Quimicas Falcon de Mexico, S.A. de C.V. (also known as Dr. Reddy’s Mexico) into the United States.” Dr. Reddy’s acknowledged receipt of the Warning Letter on June 14, 2011.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here